Hostname: page-component-cd9895bd7-p9bg8 Total loading time: 0 Render date: 2024-12-25T19:28:08.972Z Has data issue: false hasContentIssue false
  • English
  • Français

Placebo response in schizophrenia

Published online by Cambridge University Press:  16 April 2020

Τ Lewander
Τ Lewander*
Affiliation:
Astra Arcus AB, CNS Research and Development, Södertälje; Department of Psychiatry (Ulleråker), University of Uppsala, Uppsala, Sweden
Get access

Summary

A review of the literature on placebo-controlled studies in schizophrenia reveals, that the percentage of placebo responders in short-term trials amounts to 0–40%; on active treatment the response rate is 40–60%. In relapse prevention studies 18–100% of patients on placebo relapsed as compared to 0–40% on active treatment. Factors of importance for the variability between studies are discussed. Desirable designs of explanatory and pivotal studies, the importance of placebo controlled relapse prevention studies, and more rigorous assessment methods, eg video-taped and structured interviews for diagnostic and symptom rating purposes, are proposed as a means to improve the quality of the clinical documentation of new drugs.

Keywords

neurolepticsantipsychoticsplaceboschizophrenia
Type
Research Article
Information
European Psychiatry , Volume 9 , Issue 3: European Committee for Standardisation of Clinical Trials with Psychotropics, ECST Strasbourg Forum III. 10-11 June 1993, Strasbourg, France , 1994 , pp. 119 - 120
Copyright
Copyright © Elsevier, Paris 1994

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Chouinard, GJones, BRemington, Get al. A Canadian multicenter placebo-conlrolled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1992:13:25–40Google Scholar
Davis, JMAndriukaitis, SThe natural course of schizophrenia and effective maintenance drug treatment. J Clin Psychopharmacol 1986;6:2S–10SCrossRefGoogle ScholarPubMed
Delini-Stula, ABerdah-Tordjman, D Placebo controlled studies in acute schizophrenia – an issue of concern. Eur Psychiatry 1994 (in press)Google Scholar
Klein, DFDavis, JMReview of the antipsychotic drug literature.In: Klein, DFDavis, JM eds. Diagnosis and Drug Treatment of Psychiatric Disorders. Baltimore: The Williams & Wilkins Company, 52–138Google Scholar
Lapièrre, YDAncill, RAwad, AGet al. A dose-finding study with remoxipride in the acute treatment of schizophrenic patients. J Psy chiatr Neurosci 1992; 17:135–45Google ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.